Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Galapagos receives €4m milestone payment from Servier
In July 2010, Servier and Galapagos collaborated to develop new medicines for the treatment of osteoarthritis (OA). Galapagos is responsible for the discovery and development of new candidate
In July 2010, Servier and Galapagos collaborated to develop new medicines for the treatment of osteoarthritis (OA). Galapagos is responsible for the discovery and development of new candidate
Shape memory polymers are made of advanced materials which can remember more many shapes and can transit easily between those shapes with minimal force and without loss of
Salix has a license to the HIV-associated diarrhea indication for Crofelemer and the additional indications of pediatric diarrhea and acute infectious diarrhea in North America, Europe and Japan.
MolecularMD has exclusively licensed the commercial rights to this property which covers methods for detecting the EGFR T790M mutation. The new patent describes methods of detecting the EGFR
The broad claims in the patent provide protection until 2028. The patent relates to a method of using recombinant C1 inhibitor (rhC1 INH), being produced either in cell
The partnership designates IGI as the developer and manufacturer of a family of prescription topical drug products owned by Medimetriks. In addition, as part of this long term
Four doses of GP MDI were compared to placebo and Atrovent HFA Inhalation Aerosol, a short-acting muscarinic antagonist given four times a day (QID). All doses of GP
The study looks at the efficacy of the drug as well as continuing to look at the safety profile established in the Phase 1 trial. BC-IBU-CH-001 is a
The multinational, prospective, randomized, double-blind study will evaluate the effectiveness of AMR101 in reducing the prevalence of first major cardiovascular events in a high-risk patient population. Amarin chairman
The patent covers pharmaceutical compositions of a DNA cross-linker (stabilized active metabolite of ifosfamide), including palifosfamide (Zymafos or ZIO-201) and their use in treating cancer. The company has